Amicus Stock Today

FOLD -  USA Stock  

USD 7.57  0.38  4.78%

Market Performance
0 of 100
Odds Of Distress
Less than 44
Amicus Therapeutics is trading at 7.57 as of the 28th of May 2022, a -4.78 percent decrease since the beginning of the trading day. The stock's lowest day price was 7.34. Amicus Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Amicus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2022 and ending today, the 28th of May 2022. Click here to learn more.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 278.64 M outstanding shares of which 27.17 M shares are currently shorted by private and institutional investors with about 7.31 trading days to cover. More on Amicus Therapeutics
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Amicus Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Amicus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Amicus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Amicus Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 305.51 M. Net Loss for the year was (250.46 M) with profit before overhead, payroll, taxes, and interest of 271.05 M.
Amicus Therapeutics currently holds about 482.5 M in cash with (202.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Amicus Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from www.investorsobserver.com: What is the Markets View on Amicus Therapeutics, Inc. Stocks Price and Volume Trends Friday - InvestorsObserver
Amicus Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Amicus Therapeutics SEC Filings
Amicus Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Chairman and CEOJohn Crowley  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Amicus Therapeutics report their recommendations after researching Amicus Therapeutics' financial statements, talking to executives and customers, or listening in on Amicus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Amicus Therapeutics. The Amicus consensus assessment is calculated by taking the average forecast from all of the analysts covering Amicus Therapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Amicus Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Amicus Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares225 M271.4 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted225 M271.4 M
Significantly Down
Increasing
Slightly volatile
Total Assets819.6 M905.1 M
Moderately Down
Increasing
Slightly volatile
Total Liabilities513.6 M597.8 M
Fairly Down
Increasing
Slightly volatile
Current Assets504.1 M596.8 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities119.2 M146 M
Significantly Down
Increasing
Slightly volatile
Total Debt474.9 M440.1 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.860.887
Sufficiently Down
Decreasing
Slightly volatile
Asset Turnover0.380.353
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Amicus Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Amicus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Amicus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amicus Therapeutics' financial leverage. It provides some insight into what part of Amicus Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Amicus Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Amicus Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Amicus Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 440.13 M in liabilities with Debt to Equity (D/E) ratio of 1.43, which is about average as compared to similar companies. Amicus Therapeutics has a current ratio of 4.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Amicus Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Amicus Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amicus Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amicus to invest in growth at high rates of return. When we think about Amicus Therapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(218.48 Million)Share
Amicus Therapeutics (FOLD) is traded on NASDAQ Exchange in USA. It is located in 3675 Market Street and employs 496 people. Amicus Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amicus Therapeutics's market, we take the total number of its shares issued and multiply it by Amicus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Amicus Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 278.64 M outstanding shares of which 27.17 M shares are currently shorted by private and institutional investors with about 7.31 trading days to cover. Amicus Therapeutics currently holds about 482.5 M in cash with (202.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72.
Check Amicus Therapeutics Probability Of Bankruptcy
Ownership
Amicus Therapeutics holds a total of two hundred seventy-eight million six hundred fourty thousand outstanding shares. The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or about to change at the company. Also note that nearly thirty million six hundred fifty thousand four hundred invesors are currently shorting Amicus Therapeutics expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Amicus Ownership Details

Amicus Stock Price Odds Analysis

What are Amicus Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Amicus Therapeutics jumping above the current price in 90 days from now is about 75.39%. The Amicus Therapeutics probability density function shows the probability of Amicus Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4356. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Amicus Therapeutics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Amicus Therapeutics is significantly underperforming DOW.
  Odds Below 7.57HorizonTargetOdds Above 7.57
24.51%90 days
 7.57 
75.39%
Based on a normal probability distribution, the odds of Amicus Therapeutics to move above the current price in 90 days from now is about 75.39 (This Amicus Therapeutics probability density function shows the probability of Amicus Stock to fall within a particular range of prices over 90 days) .

Amicus Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Amicus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amicus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amicus Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Perceptive Advisors LlcCommon Shares27.6 M261 M
Wellington Management Group LlpCommon Shares26.6 M252.1 M
View Amicus Therapeutics Diagnostics

Amicus Therapeutics Historical Income Statement

Amicus Therapeutics Income Statement is one of the three primary financial statements used for reporting Amicus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Amicus Therapeutics revenue and expense. Amicus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Amicus Therapeutics Gross Profit is projected to increase significantly based on the last few years of reporting. The past year's Gross Profit was at 271.05 Million. The current year Interest Expense is expected to grow to about 35 M, whereas Cost of Revenue is forecasted to decline to about 28.7 M. View More Fundamentals

Amicus Stock Against Markets

Picking the right benchmark for Amicus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Amicus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Amicus Therapeutics is critical whether you are bullish or bearish towards Amicus Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Amicus Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Amicus Therapeutics Corporate Directors

Amicus Therapeutics corporate directors refer to members of an Amicus Therapeutics board of directors. The board of directors generally takes responsibility for the Amicus Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Amicus Therapeutics' board members must vote for the resolution. The Amicus Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Robert Essner - Independent DirectorProfile
Craig Wheeler - Independent DirectorProfile
Burke Whitman - Independent DirectorProfile
Margaret McGlynn - Independent DirectorProfile

Investing Amicus Therapeutics

You need to understand the risk of investing before taking a position in Amicus Therapeutics. The danger of trading Amicus Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amicus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amicus Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amicus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Investing Opportunities. Note that the Amicus Therapeutics information on this page should be used as a complementary analysis to other Amicus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Amicus Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.